StockData
Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc. (CADL) stock

CADLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 1/30
$5.40−0.41 (-7.06%)

Close on Nov 17, 2026Market cap $413.20MP/E –Yield –

Candel Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Candel Therapeutics's enterprise value was $500.25M on Nov 11, 2026, against $179.12M a year earlier. Over the last 5 years it ranged from -$33.02M to $793.30M, with a median of $149.27M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$500.25M+120.0%
2025Dec 31, 2025$227.42M-17.6%
2024Dec 31, 2024$276.10M+1301.4%
2023Dec 29, 2023$19.70M–
2022Dec 30, 2022-$25.73M-119.0%
2021Dec 31, 2021$135.55M–

More Candel Therapeutics figures

See a number that looks wrong?